Surfactant therapy in acute respiratory distress syndrome

Biology of the Neonate

Volumn 74, Issue SUPPL. 1, 1998, Pages 15-20

  Spragg, Roger G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUNG SURFACTANT; SURFACTANT;

CONFERENCE PAPER; DRUG EFFICACY; LUNG INJURY; NEONATAL RESPIRATORY DISTRESS SYNDROME; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME;

ADULT; ANIMALS; HUMANS; INFANT, NEWBORN; LUNG DISEASES; PHOSPHOLIPIDS; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, ADULT; RESPIRATORY DISTRESS SYNDROME, NEWBORN;

EID: 0031670367     PISSN: 00063126     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047030     Document Type: Conference Paper

References (55)

1. Hallman M, Spragg RG, Harrell JH, Moser KM, Gluck L: Evidence of lung surfactant abnormality in respiratory failure: Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol, J Clin Invest 1982;70:673-683.
2. King RJ: Pulmonary surfactant. J Appl Physiol 1982;53:1-8.
3. Shelley SA, Balis JU, Paciga JE, Espinoza CG, Richman AV: Biochemical composition of adult human lung surfactant. Lung 1982;160: 195-206.
4. Harris JD, Jackson FJ, Moxley MA, Longmore WJ: Effect of exogenous surfactant instillation on experimental acute lung injury. J Appl Physiol 1989;66:1846-1851.
5. Beppu OS, Clements JA, Goerke J: Phosphatidylglycerol-deficient lung surfactant has normal properties. J Appl Physiol 1983;55:496-502.
6. Yu S, Harding GR, Smith M, Possmayer F: Bovine pulmonary surfactant: Chemical composition and physical properties. Lipids 1983;18: 522-529.
7. Petty TL, Reiss OK, Paul GW, Silvers GW, Elkins ND: Characteristics of pulmonary surfactant in adult respiratory distress syndrome associated with trauma and shock. Am Rev Respir Dis 1977;115:531-536.
8. Gregory TJ, Longmore WJ, Moxley MA, Whitsett JA, Reed CR, Fowler AAI, Hudson LD, Maunder RJ, Crim C, Hyers TM: Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991; 88:1976-1981.
9. Pison U, Seeger W, Buchhorm R, Joka T, Brand M, Obertacke U, Neuhof H, Schmit-Neuerburg KP: Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis 1989;140:1033-1039.
10. Pison U, Overtacke U, Brand M, Seeger W, Joka T, Bruch J, Schmit-Neuerburg KP: Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of acute respiratory failure. J Trauma 1990;30:19-26.
11. Seeger W, Pison U, Buchhorn R, Obertacke U, Joka T: Surfactant abnormalities and adult respiratory failure. Lung 1990;168(suppl):891-902.
12. Holm BA, Enhorning G, Notter RH: A biophysical mechanism by which plasma proteins inhibit lung surfactant activity. Chem Phys Lipids 1988;49:49-55.
13. Holm BA, Keicher L, Liu MY, Sokolowski J, Enhorning G: Inhibition of pulmonary surfactant function by phospholipases. J Appl Physiol 1991;71:317-321.
14. Cifuentes J, Ruiz-Oronoz J, Myles C, Nieves B, Carlo WA, Matalon S: Interaction of surfactant mixtures with reactive oxygen and nitrogen species. J Appl Physiol 1995;78: 1800-1805.
15. Haddad IY, Zhu S, Ischiropoulos H, Matalon S: Nitration of surfactant protein A results in decreased ability to aggregate lipids. Am J Physiol 1996;270:L281-L288.
16. Gilliard N, Heldt GP, Loredo J, Gasser H, Redl H, Merritt TA, Spragg RG: Exposure of the hydrophobic components of porcine lung surfactant to oxidant stress alters surface tension properties. J Clin Invest 1994;93:2608-2615.
17. Fong LG, Parthasarathy S, Witztum JL, Steinberg D: Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J Lipid Res 1987; 28:1466-1477.
18. Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL: Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990;10:325-335.
19. Veldhuizen RA, McCaig LA, Akino T, Lewis JF: Pulmonary surfactant subfractions in patients with the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995; 152:1867-1871.
20. Enhorning G, Duffy LC, Welliver RC: Pulmonary surfactant maintains patency of conducting airways in the rat. Am J Respir Crit Care Med 1995;151:554-556.
21. Lachmann B, van Daal GJ: Adult respiratory distress syndrome: Animal models; in Robertson B, Van Golde LMG, Batenburg JJ (eds): Pulmonary Surfactant: From Molecular Biology to Clinical Practice. New York, Elsevier, 1992, pp 635-663.
22. Lachmann B, Robertson B, Vogel J: In vivo lung lavage as an experimental model of the respiratory distress syndrome. Acta Anaesthesiol Scand 1980;24:231-236.
23. Matalon S, Holm BA, Notter RH: Mitigation of pulmonary hyperoxic injury by administration of exogenous surfactant. J Appl Physiol 1987;62:756-761.
24. Engstrom PC, Holm BA, Matalon S: Surfactant replacement attenuates the increase in alveolar permeability in hyperoxia. J Appl Physiol 1989; 67:688-693.
25. Loewen GM, Holm BA, Milanowski L, Wild LM, Notter RH, Matalon S: Alveolar hyperoxic injury in rabbits receiving exogenous surfactant. J Appl Physiol 1989;66:1087-1092.
26. Huang YC, Caminiti SP, Fawcett TA, Moon RE, Fracica PJ, Miller FJ, Young SL, Piantadosi CA: Natural surfactant and hyperoxic lung injury in primates. I. Physiology and biochemistry. J Appl Physiol 1994; 76:991-1001.
27. Lewis JF, Ikegami M, Jobe AH: Metabolism of exogenously administered surfactant in the acutely injured lungs of adult rabbits. Am Rev Respir Dis 1992;145:19-23.
28. Lamm WJ, Albert RK: Surfactant replacement improves lung recoil in rabbit lungs after acid aspiration. Am Rev Respir Dis 1990;142:1279-1283.
29. Berry D, Ikegami M, Jobe A: Respiratory distress and surfactant inhibition following vagotomy in rabbits. Am J Physiol 1986;61:1741-1748.
30. van Daal GJ, So KL, Gommers D, Eijking EP, Fievez RB, Sprenger MJ, van Dam DW, Lachmann B: Intratracheal surfactant administration restores gas exchange in experimental adult respiratory distress syndrome associated with viral pneumonia. Anesth Analg 1991;72: 589-595.
31. Eijking EP, Strayer DS, van Daal GJ, Tenbrinck R, Merritt TA, Hannappel E, Lachmann B: In vivo and in vitro inactivation of bovine surfactant by an anti-surfactant monoclonal antibody. Eur Respir J 1991; 4:1245-1250.
32. Davis AJ, Jobe AH, Hafner D, Ikegami M: Lung function in premature lambs and rabbits treated with a recombinant SP-C surfactant. Am J Respir Crit Care Med 1998;157: 553-559.
33. Hawgood S, Ogawa A, Yukitake K, Schlueter M, Brown C, White T, Buckley D, Lesikar D, Benson B: Lung function in premature rabbits treated with recombinant human surfactant protein-C. Am J Respir Crit Care Med 1996;154:484-490.
34. Berggren P, Lachmann B, Curstedt T, Grossmann G, Robertson B: Gas exchange and lung morphology after surfactant replacement in experimental adult respiratory distress syndrome induced by repeated lung lavage. Acta Anaesthesiol Scand 1986;30:321-328.
35. Krause M, Olsson T, Law AB, Parer RA, Lindstrom DP, Sundell HW, Cotton RB: Effect of volume recruitment on response to surfactant treatment in rabbits with lung injury. Am J Respir Crit Care Med 1997;156:862-866.
36. Alvarez FJ, Alfonso LF, Gastiasoro E, Lopez-Heredia J, Arnaiz A, Vallsi-Soler A: The effects of multiple small doses of exogenous surfactant on experimental respiratory failure induced by lung lavage in rats. Acta Anaesthesiol Scand 1995;39.970-974.
37. Feddersen CO, von Wiehert P: Glukokortikoide bei Erkrankungen der Lunge und der Bronchien. Prax Klin Pneumol 1987;41:197-210.
38. McGuire WW, Spragg RG, Cohen AB, Cochrane CG: Studies on the pathogenesis of the adult respiratory distress syndrome. J Clin Invest 1982;69:543-553.
39. Merritt TA, Cochrane CG, Holcomb K, Bohl B, Hallman M, Strayer D, Edwards DK, Gluck L: Elastase and alpha I-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome. Role of inflammation in the pathogenesis of bronchopulmonary dysplasia. J Clin Invest 1983;72: 656-666.
40. Speer CP, Gotze B, Curstedt T, Robertson B: Phagocytic functions and tumor necrosis factor secretion of human monocytes exposed to natural porcine surfactant (Curosurf). Pediatr Res 1991;30:69-74.
41. Jobe AH: Pulmonary surfactant therapy. N Engl J Med 1993;328: 861-868.
42. Anzueto A, Baughman R, Guntupalli KK, Weg JG, Wiedemann HP, Raventos AA, Lemaire F, Long W, Zaccardelli DS, Pattishall EN: Aerosolized surfactants in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996; 334:1417-1421.
43. Lewis JF, Tabor B, Ikegami M, Jobe A, Joseph M, Absalom D: Lung function and surfactant distribution in saline lavaged sheep given instilled vs. nebulized surfactant. J Appl Physiol 1993;74:1256-1264.
44. Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore WJ, Moxley MA, Cai GZ, Hite RD, Smith RM, Hudson LD, Crim C, Newton P, Mitchell BR, Gold AJ: Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997;155:1309-1315.
45. Willson DF, Jiao JH, Bauman LA, Zaritsky A, Craft H, Dockery K, Conrad D, Dalton H: Calf's lung surfactant extract in acute hypoxemic respiratory failure in children. Crit Care Med 1996;24:1316-1322.
46. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, LeGall JR, Morris A, Spragg R: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818-824.
47. Hafner D, Beume R, Kilian U, Krasznai G, Lachmann B: Dose-response comparisons of five lung surfactant factor (LSF) preparations in an animal model of adult respiratory distress syndrome (ARDS). Br J Pharmacol 1995;115:451-458.
48. Cochrane CG, Revak SD, Merritt TA, Heldt GP, Hallman M, Cunningham MD, Easa D, Pramanik A, Edwards DK, Alberts MS: The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med 1996;153:404-410.
49. Novick RJ, Gilpin AA, Gehman KE, Ali IS, Veldhuizen RA, Duplan J, Denning L, Possmayer F, Bjarneson D, Lewis JF: Mitigation of injury in canine lung grafts by exogenous surfactant therapy. J Thorac Cardiovasc Surg 1997;113:342-353.
50. Loewen GM, Holm BA, Milanowski L, Wild LM, Notter RH, Matalon S: Alveolar hyperoxic injury in rabbits receiving exogenous surfactant. J Appl Physiol 1989;66:1087-1092.
51. Huang YC, Sane AC, Simonson SG, Fawcett TA, Moon RE, Fracica PJ, Menache MG, Piantadosi CA, Young SL: Artificial surfactant attenuates hyperoxic lung injury in primates. I. Physiology and biochemistry. J Appl Physiol 1995;78: 1816-1822.
52. Piantadosi CA, Fracica PJ, Duhaylongsod FG, Huang YC, Welty-Wolf KE, Crapo JD, Young SL: Artificial surfactant attenuates hyperoxic lung injury in primates. II. Morphometric analysis. J Appl Physiol 1995;78: 1823-1831.
53. Tanswell AK, Freeman BA: Liposome-entrapped antioxidant enzymes prevent lethal oxygen toxicity in the newborn rat. J Appl Physiol 1987;63:347-352.
54. von Wichert P, Muller B, Meyer-Ingold W: Influence of a beta-adrenergic agonist on septic shock-induced alterations of phosphatidylcholine metabolism in rat lung. Lung 1988;166:257-267.
55. Ohashi T, Takada S, Motoike T, Tsuneishi S, Matsuo M, Sano K, Nakamura H: Effect of dexamethasone on pulmonary surfactant metabolism in hyperoxia-treated rat lungs. Pediatr Res 1991;29:173-177.